8/5 Taiwan Life Sciences Biweekly Newsletter
2024-08-05 |
| Taiwan Life Sciences Biweekly |
| JelloX Biotech collaborates with Mayo Clinic to develop AI enhanced 3D pathology imaging technology Press release 31 July, 2024 JelloX Biotech Inc. is pleased to announce that it has entered into a collaboration through a know-how agreement with Mayo Clinic to further develop and validate their 3D digital imaging and AI analysis technology. JelloX previously participated in the fifth cohort of the Mayo Clinic and Arizona State University Alliance for Health Care MedTech Accelerator, a flagship program providing early-stage medical device and healthcare technology companies with curriculum to accelerate their go-to-market plans. JelloX has developed a 3D pathology imaging technology with artificial intelligence (AI) for spatial analysis to support precision cancer diagnosis. More... |
| Excelsior Bio-System's animal testing products enter South Korea market 31 July, 2024 Allergen testing company Excelsior Bio-System reports that it has successfully expanded into domestic and foreign markets. In the human testing section, the company's revenue in the first half of the year increased by 16 percent YoY. In addition, the company's new pet testing products will enter into the South Korean market and have already received local orders. More... (in Chinese) |
| Taiwan Biotechnology Shines Internationally 31 July, 2024 Following high-value licensing agreements from the likes of Alar Pharmaceuticals, Oneness Biotech, PharmaEngine, and others, and with their products beginning to generate respectable revenues, Taiwan’s biotech sector is gaining international recognition. Taiwan-based Tantti Laboratory was recently acquired by the US company Repligen, highlighting the growing global presence of Taiwanese companies in this sector. Industry experts believe that licensing deals, mergers and acquisitions will help propel the biotech industry to the world stage. More... (in Chinese) |
| Gongxin's pet cancer medication a step closer to market entry 30 July, 2024 Gongwin BioPharm (TW: 6617) announced that its new animal targeted tumor ablation drug injection has been submitted to the Taiwan drug authorities for a marketing license, officially announcing its entry into the highly-undeveloped market of pet cancer drugs. Based on the normal application review period, Gongwin BioPharm has the opportunity to obtain a drug license in the first half of 2025. More... (in Chinese) |
| BIO Asia-Taiwan 2024 concludes successfully 30 July, 2024 BIO Asia-Taiwan 2024 concluded successfully on Monday, with the dates for next year's event announced; BIO Asia-Taiwan 2025 will be held in Taipei on July 23-27. Wrapping up the event, Chairman of BIO Asia-Taiwan Johnsee Lee said that Taiwan's importance in biotechnology development in Asia had been well recognized internationally, and he looks forward to continuing to provide a communication platform for Asia's bio-industry ecosystem in the years ahead. Even with two days of typhoon disruption, BIO Asia-Taiwan this year had about 900 exhibitors, with the number of booths exceeding 2,200. Event participants booked more than 8,000 one-on-one business meetings, an increase of 70 percent year-on-year. The number of visitors to the full schedule of events including the exhibition 120,000, setting another new record. On the first day of the conference, more than 2,000 people participated, 40 percent of whom were from abroad, with Japan, the United States, and South Korea making up the largest number of participants. More... (in Chinese) |
| MOEA, ASOA stage biotechnology medical industry event 30 July, 2024 The Small and Medium Enterprise and Startup Administration under the Ministry of Economic Affairs and Taipei City-based American State Offices Association jointly organized a biotechnology and medical care forum July 26 in Taipei City to explore future cooperation opportunities between Taiwan and the U.S. More... |
| Biosimilar drug sector summit held at BIO Asia-Taiwan 2024 30 July, 2024 The Taiwan Nongovermental Hospitals and Clinics Association and the Biosimilars Committee of the Taiwan Bio Industry Organization (Taiwan BIO) jointly organized a summit entitled 'Advanced Biosimilar Usage in Taiwan: Global Insights and Local Strategies', one of the official Satellite Symposia of BIO Asia-Taiwan this year More... (in Chinese) |
| New CDMO Taiwan Bio-Manufacturing Corporation competes in Startup World Cup, forms strategic alliance with US and Japan to build an Asian production base 29 July, 2024 At the BIO Asia-Taiwan 2024 gathering, Taiwan Bio-Manufacturing Corporation (TBMC) CEO David Chang announced that the company had formed an alliance with CMIC Bio, Japan’s largest commissioned clinical research (CRO) company, and Thermo Fisher Scientific of the United States. Together with its strategic partner Resilience of the United States, TBMC intends to continue to make inroads into the international CDMO market. Chang announced that it will cooperate with Japan's CMIC Bio company to jointly enter the Japanese market through the CHO-C antibody production platform. And with Thermo Fisher Scientific it intends to use the company's instruments and equipment to improve advanced drug research and development and manufacturing technology to provide high-quality services to global customers. More... (in Chinese) |
| Super-aged Precision Regenerative Medicine Project unveils midterm results 29 July, 2024 Seven medical research teams announced super-aged precision regenerative medicine research results on July 27 during the BIO Asia–Taiwan 2024 at Taipei Nangang Exhibition Center, according to the National Science and Technology Council. The teams include Taipei City-based Academia Sinica, National Taiwan University and Yang Ming Chiao Tung University, New Taipei City-based Far Eastern Memorial Hospital, Taoyuan City-based Chang Gung University, Taichung City-based China Medical University and Tainan City-based National Cheng Kung University. More... |
| 2024 Taiwan BIO Awards Announced: 19 companies and technologies win recognition 29 July, 2024 The Taiwan Bio-Industry Organization (Taiwan BIO)-organized 2024 Taiwan BIO Awards category winners were announced today. After three months of preliminary review, re-examination and final review, a total of 19 institutions and product technologies were selected. Among them, Lotus Pharmaceuticals, PharmaEssentia Pharmaceuticals and Bonraybio won the 'Outstanding Company of the Year' award this year. More... (in Chinese) |
| Two promising anti-cancer products transferred to industry: MOEA 28 July, 2024 At the BIO Asia-Taiwan 2024 exhibition, the Department of Industrial Technology of the Ministry of Economic Affairs (MOEA) held a press conference and announced two major local developments in cancer medical research. First, the Development Center for Biotechnology (DCB) had authorized LAUNXP Biomedical to develop its novel FLT3 inhibitor to treat leukemia. The other was ITRI's High-Precision Blood Gene Testing technology which had been transferred to LabTurbo Biotech Corporation for further development. More... (in Chinese) |
| Taiwan VP Hsiao Commends Taiwan's Biotech and Biomedical Capabilities, Expects Continued Global Integration of Taiwan's Biotech Industry 28 July, 2024 Taiwan Vice President Hsiao Mei-chin visited the BIO Asia-Taiwan 2024 Exhibition at the Nangang Exhibition Center (TaiNEX 1) this morning (28th) to learn about the latest technologies and equipment in the biotechnology field. She affirmed Taiwan's strong biomedical capabilities and expressed her trust that the exhibition would assist Taiwanese biotechnology companies and institutions to better connect with their international counterparts. Upon her arrival, the Vice President presented awards to the winners of this year's Taiwan BIO Awards in the categories "Outstanding Company of the Year," "Emerging Company of the Year," "Startup of the Year," and "Innovation of the Year." She then toured the exhibition, including the "Contract Development and Manufacturing Services," "Precision Medicine and Genetic Testing," "International Pavilions," "Government and Academic Research," and "Industry-Academia Incubation" specialty zones, to witness the full biotechnology industry chain from research and development to finished product stage, in addition to taking in some of the latest emerging technologies and equipment. She praised Taiwan's biomedical capabilities and looked forward to the exhibition attracting and encouraging exchanges and cooperation from key biotechnology companies both domestically and internationally. More... (in Chinese) |
| BIO Asia-Taiwan 2024 Kicks Off: Taiwan and Malaysia Hope to Build Collaborative Bridges 27 July, 2024 The BIO Asia-Taiwan 2024 Exhibition kicked off on the 26th of July, this year featuring over 2,200 booths. The Malaysia External Trade Development Corporation (MATRADE) organized the Malaysia segment of the Regional Collaboration Forum series of BIO Asia-Taiwan, to promote cooperation between the biotech industries of Taiwan and Malaysia. Malaysia's chief representative, Aisyah, highlighted that the Malaysian government continues to support the medical device and bioeconomy industries, with expectations for the market size to reach USD43.2 billion by 2030. More... (in Chinese) |
| Taiwan's 'miracle mushroom' Antrodia cinnamomea for hangover relief and liver health in Asia 25 July, 2024 Taiwan's Greenyn Biotechnology is working to get regulatory approvals in key Asia markets for Antrodia cinnamomea, after the so-called 'miracle mushroom' was found to improve the liver function of regular drinkers and chronic Hep B patients in trials funded by the firm. More... |
| Taiwan advances innovative drug delivery technology for diabetes treatment 25 July, 2024 Taiwan-based startup Merdury Biopharmaceutical Corporation has signed a Memorandum of Understanding (MoU) with Health2Sync, Asia's largest chronic disease management platform. In this collaboration, the two parties aim to enhance the clinical evidence supporting the superior pharmacokinetic profile of oral semaglutide when delivered by Merdury's StackDose technology. More... |
| 2024 Bio Asia-Taiwan conference opens in Taipei 24 July, 2024 The 2024 Bio Asia-Taiwan International Conference and Exhibition opened at the Nangang Exhibition Center in Taipei on Wednesday, kicking off five days of talks and activities showcasing the latest developments in the biotech industry. More... |
| GC Cell, Lukas Biomedical to cooperate on immune cell therapy development 22 July, 2024 GC Cell said it has signed a strategic cooperation agreement with Taiwan's Lukas Biomedical to develop and expand the market for immune cell therapies. Lukas Biomedical is an advanced biotechnology company in Taiwan. It is conducting a phase 2 clinical trial of LuLym-T, an immune cell therapy using autologous CIK T cells, as a post-surgical treatment for liver cancer, based on technology transferred from GC Cell's subsidiary GC LTEC and Japan's National Cancer Center. More... |
| ========================================= |
| Taiwan Bio Industry Organization (Taiwan BIO) Contact: Daisy Tsai Tel: +886 2 27836028 ext 14 FAX : +886 2 27836027 Mobile: +886 933-139647 | Line ID : daisy222 Email: daisy@taiwanbio.org.tw BIO Asia-Taiwan 2024 (24-28 July, 2024) ========================================= Taiwan Bio Industry Organization (TBIO) Room C229, Bldg. C, No.99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei, Taiwan (11571) ========================================= |